Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Florian Groelly

Postdoctoral Researcher in Genome Stability


Mutations in BRCA1 and BRCA2 are found in familial and sporadic cancers. BRCA1/2 play key role in DNA damage response (DDR) by promoting homologous recombination (HR) and protecting stalled replication forks. My research projects aim to identify causes of DNA damage in cells lacking BRCA1/2 and to understand their consequences. Indeed, S phase DNA damage can be carried over and transmitted to daughter cells. As an example, we recently showed that BRCA2 loss causes micronuclei formation and activates a type I immune response (Reisländer et al., 2019). A current aspect of my research is to understand how BRCA2 protects from mitotic DNA breaks, and thus prevents micronuclei formation in healthy tissues. Ultimately, this would bring a better understanding of the role of BRCA1/2 and inform on new biomarkers or treatment strategies.

© F. Groelly
Roles of BRCA1 and BRCA2 on stalled replication forks.


Reisländer, T., Lombardi, E.P.#, Groelly, F.J.# et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun 10, 3143 (2019).